The US Lymphoma drugs market size stood at USD 5.7 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
According to Leukemia & Lymphoma Society, in 2019, 82,310 new cases of lymphoma and 8,110 & 74,200 cases of Hodgkin & Non-Hodgkin Lymphoma (NHL), respectively, are expected to be diagnosed in the U.S. Moreover, it is estimated that there are 874,730 people in remission or are living with lymphoma in the U.S. The 5-year survival rate of patients with Hodgkin Lymphoma (HL) has more than doubled. The survival rate is 93.9% for patients with HL aged 45 and below at diagnosis. It has been estimated that in 2019, about 20,970 people in the U.S. are likely to die from lymphoma.
Increasing Usage of premium products including Keytruda, Opdivo, and immune checkpoint inhibitors is among some of the key factors, that is expected to drive market growth. Advances in therapeutical approaches and the continuous innovation of therapies are among other factors driving growth.
Major pharmaceutical companies functioning in the oncology field are focusing on progressive strategic plans such as acquisitions & mergers with other companies to consolidate their foothold in the US lymphoma market. In 2015 for instance, in cancer therapeutics market, the market players engaged into numerous collaborations and mergers, reflecting an increasing interest of various players in this domain. Numerous organizations and research institutes on are collaborating with one another in order to develop novel and innovative therapies for treatment of lymphoma disease.